Protocol Ledger

NCT06111014 · Phase III · TERMINATED

Continuation Study for Latozinemab

Interventional Phase III clinical trial protocol NCT06111014 sponsored by Alector in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-08 Enrollment: 17 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06111014
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)17 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06111014
Protocol FieldVerified Registry Value
NCT IdentifierNCT06111014
Consolidated Lead SponsorAlector
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment17 participants (ACTUAL)
Registered Start Date2023-12-08
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06111014
Hospital Research SiteLocationSite Profile
University of Pennsylvania Abramson Cancer CenterPhiladelphia, PAOpen Hospital Dossier ->
UZ LeuvenLeuven, BelgiumOpen Hospital Dossier ->
Sunnybrook Health Sciences CentreToronto, CanadaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI